Retrospective Analysis

Frequency, Interval, and Patient Factors Associated With Recurrence of Disseminated Cutaneous Coccidioidomycosis

mycolabadmin

This study looked at how often a serious fungal skin infection called coccidioidomycosis comes back after treatment. Researchers found that about 25% of patients experienced at least one recurrence after stopping antifungal medications, with the average time before it returned being 14 months. Some patients had multiple recurrences, and most of the time the infection returned to the same location on the body.

Clinical Outcomes of Micafungin for Invasive Fungal Infections in the Obese and Nonobese

mycolabadmin

This study examined whether obese patients treated with the antifungal drug micafungin for serious fungal infections had different outcomes compared to non-obese patients. Researchers reviewed 378 patient cases and found that both groups had similar success rates of about 50%, suggesting that the standard dose of micafungin works equally well in obese and non-obese patients. These findings suggest that doctors do not need to prescribe higher doses of micafungin specifically for obese patients, though more research is needed to fully understand how obesity affects antifungal treatment.

Research Keyword: Retrospective Analysis

Frequency, Interval, and Patient Factors Associated With Recurrence of Disseminated Cutaneous Coccidioidomycosis

Clinical Outcomes of Micafungin for Invasive Fungal Infections in the Obese and Nonobese